Search details
1.
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
N Engl J Med
; 390(19): 1781-1792, 2024 May 16.
Article
in English
| MEDLINE | ID: mdl-38587247
2.
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
N Engl J Med
; 390(19): 1770-1780, 2024 May 16.
Article
in English
| MEDLINE | ID: mdl-38587249
3.
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
N Engl J Med
; 382(3): 244-255, 2020 01 16.
Article
in English
| MEDLINE | ID: mdl-31893580
4.
On-treatment platelet reactivity through the thromboxane A2 or P2Y12 platelet receptor pathways is not affected by pelacarsen.
J Thromb Thrombolysis
; 56(2): 226-232, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37338713
5.
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
Eur Heart J
; 43(14): 1401-1412, 2022 04 06.
Article
in English
| MEDLINE | ID: mdl-35025993
6.
Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia.
N Engl J Med
; 390(5): 476-477, 2024 Feb 01.
Article
in English
| MEDLINE | ID: mdl-38294982
7.
Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.
Lipids Health Dis
; 20(1): 174, 2021 Dec 05.
Article
in English
| MEDLINE | ID: mdl-34865644
8.
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Eur Heart J
; 41(40): 3936-3945, 2020 10 21.
Article
in English
| MEDLINE | ID: mdl-32860031
9.
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. Reply.
N Engl J Med
; 382(21): e65, 2020 05 21.
Article
in English
| MEDLINE | ID: mdl-32433854
10.
Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.
Europace
; 17(1): 32-7, 2015 Jan.
Article
in English
| MEDLINE | ID: mdl-25210025
11.
The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine.
Europace
; 15(3): 429-36, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23258816
12.
Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2'-MOE and Phosphorothioate Modified Antisense Oligonucleotides.
J Clin Pharmacol
; 63(1): 21-28, 2023 01.
Article
in English
| MEDLINE | ID: mdl-35801818
13.
Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects.
J Clin Lipidol
; 17(1): 181-188, 2023.
Article
in English
| MEDLINE | ID: mdl-36529659
14.
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
J Clin Lipidol
; 17(3): 406-411, 2023.
Article
in English
| MEDLINE | ID: mdl-37164837
15.
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol.
J Am Coll Cardiol
; 79(11): 1035-1046, 2022 03 22.
Article
in English
| MEDLINE | ID: mdl-35300814
16.
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.
J Clin Lipidol
; 16(5): 617-625, 2022.
Article
in English
| MEDLINE | ID: mdl-35902351
17.
Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
Circulation
; 122(5): 455-62, 2010 Aug 03.
Article
in English
| MEDLINE | ID: mdl-20644019
18.
Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen.
Atherosclerosis
; 324: 102-108, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33872986
19.
Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.
Circulation
; 119(15): 2032-9, 2009 Apr 21.
Article
in English
| MEDLINE | ID: mdl-19349325
20.
Treatment with Volanesorsen, a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers.
Nucleic Acid Ther
; 30(4): 198-206, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32589506